Asia Pacific Jan 16, 2023
Beijing has acknowledged that supplies are still insufficient to meet demand, even as millions of courses of the treatment were shipped to the country recently.
Beijing has acknowledged that supplies are still insufficient to meet demand, even as millions of courses of the treatment were shipped to the country recently.
Pfizer's bivalent vaccine linked to rare strokes in older people in preliminary U.S. data
The early finding still needs more investigation, and recommendations for the vaccine have not been changed, a statement by the U.S. Food and Drug Administration said.
Beijing is in talks with the drugmaker to secure a license that will allow domestic firms to manufacture and distribute a generic version of its Paxlovid antiviral drug.
Pfizer’s RSV vaccine succeeds where others failed
Early data bodes well for Pfizer’s RSV shot, which would be given during pregnancy to protect infants in the early months of life.
Pfizer’s Paxlovid anti-viral seen to lower long-COVID risk in study
Taking the oral medication within five days of testing positive for a SARS-CoV-2 infection was linked to a 26% lower risk of lingering post-viral complications, researchers found.
Study shows new booster improves protection for older people, Pfizer says
U.S. officials are hoping that the encouraging results will improve what has so far been a dismal public response to the retooled shots.
Japan health ministry backs Pfizer and Moderna omicron boosters
Pfizer’s omicron booster can be administered to people age 12 and over, while Moderna’s is limited to those 18 and above, the panel advised.
What we know about the new omicron vaccines
New vaccines developed for the COVID-19 omicron variant are scheduled to be available from mid-October in Japan, raising hopes that the population will soon be better protected.
Shionogi confirms efficacy of oral COVID drug for omicron subvariant
The announcement came after a health ministry panel in July postponed the granting of emergency approval for the drug.
Pfizer to buy Global Blood Therapeutics in $5.4 billion deal
Pfizer will gain Oxbryta, South San Francisco-based Global Blood’s therapy for sickle-cell disease that sold about $195 million last year.
We need better COVID-19 booster shots, not more of the same
There are 100 new Covid vaccines in development. One of them could offer better protection against omicron.
China promotes traditional cures as Pfizer pill alternatives
China is struggling to persuade skeptics to put aside doubts about traditional medicine that hasn’t gone through large, standardized clinical trials.